---
document_datetime: 2025-12-02 04:50:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-mylan.html
document_name: lenalidomide-mylan.html
version: success
processing_time: 0.1426197
conversion_datetime: 2025-12-26 13:26:04.93585
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lenalidomide Mylan

[RSS](/en/individual-human-medicine.xml/67389)

##### Authorised

This medicine is authorised for use in the European Union

lenalidomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lenalidomide Mylan](#news-on)
- [Related documents](#related-documents-1603)
- [More information on Lenalidomide Mylan](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lenalidomide Mylan is a medicine used for the treatment of certain cancers affecting blood cells, namely multiple myeloma and follicular lymphoma.

In **multiple myeloma** , a cancer of a type of white blood cells called plasma cells, Lenalidomide Mylan is used:

- in adults with previously untreated (newly diagnosed) multiple myeloma, who have had a stem cell transplant (a procedure where the patient's bone marrow is cleared of cells and replaced by stem cells from a donor);
- in adults with previously untreated (newly diagnosed) multiple myeloma, who cannot have stem cell transplantation. It is used in combination with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone;
- in adults whose disease has been treated at least once. It is used in combination with dexamethasone.

In **follicular lymphoma** , a blood cancer that affects a type of white blood cell called B lymphocytes, Lenalidomide Mylan is used in adults whose disease has come back after treatment or does not improve with treatment. It is used in combination with rituximab.

Lenalidomide Mylan contains the active substance lenalidomide and is a 'generic medicine'. This means that Lenalidomide Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Revlimid.

Expand section

Collapse section

## How is Lenalidomide Mylan used?

Lenalidomide Mylan can only be obtained with a prescription and treatment should be supervised by doctors who have experience in the use of cancer medicines.

Lenalidomide Mylan is available as capsules of various strengths to be taken by mouth. Treatment is given in cycles, with the medicine being used once a day on certain days of the cycles. Treatment cycles are continued until the disease is no longer being controlled or side effects become unacceptable. The dose depends on the disease it is being used for, the patient's overall health and blood test results. The dose may need to be reduced or treatment interrupted in case of certain side effects.

For more information about using Lenalidomide Mylan, see the package leaflet or contact your doctor or pharmacist.

## How does Lenalidomide Mylan work?

The active substance in Lenalidomide Mylan, lenalidomide, is an immunomodulator. This means that it affects the activity of the immune system (the body's natural defences). Lenalidomide works in several ways: it blocks the development of abnormal cells, prevents the growth of blood vessels within tumours and also stimulates specialised cells of the immune system to attack the abnormal cells.

## How has Lenalidomide Mylan been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Revlimid, and do not need to be repeated for Lenalidomide Mylan.

As for every medicine, the company provided studies on the quality of Lenalidomide Mylan. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Lenalidomide Mylan?

Because Lenalidomide Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Lenalidomide Mylan authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Lenalidomide Mylan has been shown to have comparable quality and to be bioequivalent to Revlimid. Therefore, the Agency's view was that, as for Revlimid, the benefits of Lenalidomide Mylan outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Lenalidomide Mylan?

The company that markets Lenalidomide Mylan will provide educational kits for healthcare professionals, and brochures for patients, explaining that the medicine can be harmful to the unborn child and detailing the steps that need to be taken for the medicine to be used safely. It will also supply cards to patients about the safety measures patients should take.

The company has also set up a pregnancy prevention programme in each member state and will collect information on the medicine's use outside its approved uses. The boxes containing Lenalidomide Mylan capsules also include a warning stating that lenalidomide can be harmful to the unborn child.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lenalidomide Mylan have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lenalidomide Mylan are continuously monitored. Side effects reported with Lenalidomide Mylan are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lenalidomide Mylan

Lenalidomide Mylan received a marketing authorisation valid throughout the EU on 18 December 2020.

Lenalidomide Mylan : EPAR - Medicine overview

Reference Number: EMA/563897/2020

English (EN) (169.87 KB - PDF)

**First published:** 07/01/2021

[View](/en/documents/overview/lenalidomide-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-709)

български (BG) (189.96 KB - PDF)

**First published:**

07/01/2021

[View](/bg/documents/overview/lenalidomide-mylan-epar-medicine-overview_bg.pdf)

español (ES) (169.41 KB - PDF)

**First published:**

07/01/2021

[View](/es/documents/overview/lenalidomide-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (190.72 KB - PDF)

**First published:**

07/01/2021

[View](/cs/documents/overview/lenalidomide-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (169.15 KB - PDF)

**First published:**

07/01/2021

[View](/da/documents/overview/lenalidomide-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (173.03 KB - PDF)

**First published:**

07/01/2021

[View](/de/documents/overview/lenalidomide-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (157.5 KB - PDF)

**First published:**

07/01/2021

[View](/et/documents/overview/lenalidomide-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (190.49 KB - PDF)

**First published:**

07/01/2021

[View](/el/documents/overview/lenalidomide-mylan-epar-medicine-overview_el.pdf)

français (FR) (170.98 KB - PDF)

**First published:**

07/01/2021

[View](/fr/documents/overview/lenalidomide-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (188.3 KB - PDF)

**First published:**

07/01/2021

[View](/hr/documents/overview/lenalidomide-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (168.25 KB - PDF)

**First published:**

07/01/2021

[View](/it/documents/overview/lenalidomide-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (207.49 KB - PDF)

**First published:**

07/01/2021

[View](/lv/documents/overview/lenalidomide-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (189.86 KB - PDF)

**First published:**

07/01/2021

[View](/lt/documents/overview/lenalidomide-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (190.49 KB - PDF)

**First published:**

07/01/2021

[View](/hu/documents/overview/lenalidomide-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (192.45 KB - PDF)

**First published:**

07/01/2021

[View](/mt/documents/overview/lenalidomide-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (168.78 KB - PDF)

**First published:**

07/01/2021

[View](/nl/documents/overview/lenalidomide-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (191.64 KB - PDF)

**First published:**

07/01/2021

[View](/pl/documents/overview/lenalidomide-mylan-epar-medicine-overview_pl.pdf)

português (PT) (169.89 KB - PDF)

**First published:**

07/01/2021

[View](/pt/documents/overview/lenalidomide-mylan-epar-medicine-overview_pt.pdf)

română (RO) (187.23 KB - PDF)

**First published:**

07/01/2021

[View](/ro/documents/overview/lenalidomide-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (190.37 KB - PDF)

**First published:**

07/01/2021

[View](/sk/documents/overview/lenalidomide-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (188.51 KB - PDF)

**First published:**

07/01/2021

[View](/sl/documents/overview/lenalidomide-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (166.22 KB - PDF)

**First published:**

07/01/2021

[View](/fi/documents/overview/lenalidomide-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (167.73 KB - PDF)

**First published:**

07/01/2021

[View](/sv/documents/overview/lenalidomide-mylan-epar-medicine-overview_sv.pdf)

Lenalidomide Mylan : EPAR - Risk-management-plan

English (EN) (1.08 MB - PDF)

**First published:** 07/01/2021

**Last updated:** 17/07/2024

[View](/en/documents/rmp-summary/lenalidomide-mylan-epar-risk-management-plan_en.pdf)

## Product information

Lenalidomide Mylan : EPAR - Product information

English (EN) (678.89 KB - PDF)

**First published:** 07/01/2021

**Last updated:** 06/11/2025

[View](/en/documents/product-information/lenalidomide-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-352)

български (BG) (1.11 MB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/bg/documents/product-information/lenalidomide-mylan-epar-product-information_bg.pdf)

español (ES) (992.53 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/es/documents/product-information/lenalidomide-mylan-epar-product-information_es.pdf)

čeština (CS) (1.08 MB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/cs/documents/product-information/lenalidomide-mylan-epar-product-information_cs.pdf)

dansk (DA) (920.82 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/da/documents/product-information/lenalidomide-mylan-epar-product-information_da.pdf)

Deutsch (DE) (797.15 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/de/documents/product-information/lenalidomide-mylan-epar-product-information_de.pdf)

eesti keel (ET) (868.8 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/et/documents/product-information/lenalidomide-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (707.46 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/el/documents/product-information/lenalidomide-mylan-epar-product-information_el.pdf)

français (FR) (675.56 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/fr/documents/product-information/lenalidomide-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (797.74 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/hr/documents/product-information/lenalidomide-mylan-epar-product-information_hr.pdf)

íslenska (IS) (885.1 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/is/documents/product-information/lenalidomide-mylan-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/it/documents/product-information/lenalidomide-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (915.64 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/lv/documents/product-information/lenalidomide-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1 MB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/lt/documents/product-information/lenalidomide-mylan-epar-product-information_lt.pdf)

magyar (HU) (827.43 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/hu/documents/product-information/lenalidomide-mylan-epar-product-information_hu.pdf)

Malti (MT) (1.19 MB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/mt/documents/product-information/lenalidomide-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (955.17 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/nl/documents/product-information/lenalidomide-mylan-epar-product-information_nl.pdf)

norsk (NO) (762.41 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/no/documents/product-information/lenalidomide-mylan-epar-product-information_no.pdf)

polski (PL) (764.04 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/pl/documents/product-information/lenalidomide-mylan-epar-product-information_pl.pdf)

português (PT) (1010.54 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/pt/documents/product-information/lenalidomide-mylan-epar-product-information_pt.pdf)

română (RO) (1.1 MB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/ro/documents/product-information/lenalidomide-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (1.05 MB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/sk/documents/product-information/lenalidomide-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (654.18 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/sl/documents/product-information/lenalidomide-mylan-epar-product-information_sl.pdf)

Suomi (FI) (917.11 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/fi/documents/product-information/lenalidomide-mylan-epar-product-information_fi.pdf)

svenska (SV) (665.29 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

06/11/2025

[View](/sv/documents/product-information/lenalidomide-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000309298 06/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lenalidomide Mylan : EPAR - All authorised presentations

English (EN) (100.22 KB - PDF)

**First published:** 07/01/2021

**Last updated:** 26/07/2021

[View](/en/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-935)

български (BG) (111.72 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/bg/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (95.42 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/es/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (100.22 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/cs/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (98.53 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/da/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (105.67 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/de/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (94.2 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/et/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (109.17 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/el/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (101.39 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/fr/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (99.22 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/hr/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (296.45 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/is/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (97.18 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/it/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (96.82 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/lv/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (102.9 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/lt/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (108.54 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/hu/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (108.11 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/mt/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (101.18 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/nl/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (111.47 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/no/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (101.76 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/pl/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (98.37 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/pt/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (92.62 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/ro/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (102.36 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/sk/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (102.88 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/sl/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (94.17 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/fi/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (94.25 KB - PDF)

**First published:**

07/01/2021

**Last updated:**

26/07/2021

[View](/sv/documents/all-authorised-presentations/lenalidomide-mylan-epar-all-authorised-presentations_sv.pdf)

Lenalidomide Mylan : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (271.22 KB - PDF)

**First published:** 07/01/2021

[View](/en/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (24)](#file-language-dropdown-355)

български (BG) (245.94 KB - PDF)

**First published:**

07/01/2021

[View](/bg/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (62.37 KB - PDF)

**First published:**

07/01/2021

[View](/es/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (268.04 KB - PDF)

**First published:**

07/01/2021

[View](/cs/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (432.88 KB - PDF)

**First published:**

07/01/2021

[View](/da/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (47.45 KB - PDF)

**First published:**

07/01/2021

[View](/de/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (47.33 KB - PDF)

**First published:**

07/01/2021

[View](/et/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (353.05 KB - PDF)

**First published:**

07/01/2021

[View](/el/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (438.77 KB - PDF)

**First published:**

07/01/2021

[View](/fr/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

hrvatski (HR) (103.33 KB - PDF)

**First published:**

07/01/2021

[View](/hr/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_hr.pdf)

íslenska (IS) (296.44 KB - PDF)

**First published:**

07/01/2021

[View](/is/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (294.78 KB - PDF)

**First published:**

07/01/2021

[View](/it/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (300.45 KB - PDF)

**First published:**

07/01/2021

[View](/lv/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (270.58 KB - PDF)

**First published:**

07/01/2021

[View](/lt/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (272.95 KB - PDF)

**First published:**

07/01/2021

[View](/hu/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (304.78 KB - PDF)

**First published:**

07/01/2021

[View](/mt/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (261.78 KB - PDF)

**First published:**

07/01/2021

[View](/nl/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (366.23 KB - PDF)

**First published:**

07/01/2021

[View](/no/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (374.27 KB - PDF)

**First published:**

07/01/2021

[View](/pl/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (269.73 KB - PDF)

**First published:**

07/01/2021

[View](/pt/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (448.48 KB - PDF)

**First published:**

07/01/2021

[View](/ro/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (339.06 KB - PDF)

**First published:**

07/01/2021

[View](/sk/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (268.75 KB - PDF)

**First published:**

07/01/2021

[View](/sl/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (344.71 KB - PDF)

**First published:**

07/01/2021

[View](/fi/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (372.07 KB - PDF)

**First published:**

07/01/2021

[View](/sv/documents/conditions-member-states/lenalidomide-mylan-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Lenalidomide Mylan Active substance lenalidomide International non-proprietary name (INN) or common name lenalidomide Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L04AX07

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

**Multiple myeloma**

Lenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.

Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

**Follicular lymphoma**

Lenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).

## Authorisation details

EMA product number EMEA/H/C/005306

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Ireland Limited

Unit 35/36

Opinion adopted 15/10/2020 Marketing authorisation issued 18/12/2020 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lenalidomide Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (326.49 KB - PDF)

**First published:** 05/03/2025

**Last updated:** 06/11/2025

[View](/en/documents/procedural-steps-after/lenalidomide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lenalidomide Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (168.26 KB - PDF)

**First published:** 31/03/2021

**Last updated:** 05/03/2025

[View](/en/documents/procedural-steps-after/lenalidomide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Lenalidomide Mylan-H-C-PSUSA-00001838-202012 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/618753/2021

English (EN) (122.39 KB - PDF)

**First published:** 11/05/2022

**Last updated:** 31/05/2022

[View](/en/documents/scientific-conclusion/lenalidomide-mylan-h-c-psusa-00001838-202012-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf-0)

## Initial marketing authorisation documents

Lenalidomide Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/583241/2020

English (EN) (795.06 KB - PDF)

**First published:** 07/01/2021

[View](/en/documents/assessment-report/lenalidomide-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lenalidomide Mylan

Adopted

Reference Number: EMA/CHMP/509778/2020

English (EN) (155.51 KB - PDF)

**First published:** 16/10/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-mylan_en.pdf)

#### News on Lenalidomide Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020) 16/10/2020

#### Related documents

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Lenalidomide Mylan

- [Lenalidomide Mylan - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/lenalidomide-mylan)

**This page was last updated on** 06/11/2025

## Share this page

[Back to top](#main-content)